UBS Maintains Neutral on Oscar Health, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Neutral 67.9%

Neg 0% Neu 67.9% Pos 0%

UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $20 to $26.